Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
US11801234B2 · kind B2 · utility
4Cited by
1References
38Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 5, 2021 |
| Grant date | Oct 31, 2023 |
| Priority date | — |
| Expiry date | Nov 20, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This application describes methods of inhibiting APOL1 and treating APOL1-mediated kidney diseases comprising administering Compound I and/or a pharmaceutically acceptable salt thereof. The application also describes pharmaceutical compositions comprising Compound I and/or a pharmaceutically acceptable salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.